Cell biology and genetics of minimal change disease

Moin A Saleem1, Yasuko Kobayashi2

  • 1Paediatric Renal Medicine, University of Bristol, Bristol, UK; Children's Renal Unit, Bristol Royal Hospital for Children, Bristol, UK.

F1000Research
|April 20, 2016
PubMed

Insights

Minimal change disease (MCD) involves podocyte damage causing nephrotic syndrome. Recent research explores genetic factors and circulating factors, offering insights into disease mechanisms and potential biomarkers for treatment.

Area of Science:

  • Nephrology
  • Immunology
  • Genetics

Background:

  • Minimal change disease (MCD) is a primary cause of nephrotic syndrome, characterized by massive proteinuria and podocyte injury.
  • The pathogenesis of MCD is complex, with proposed roles for immunologic disturbances, including T and B lymphocyte dysfunction.
  • While genetic defects were initially considered less likely, recent advances have identified mutations in familial cases of steroid-sensitive nephrotic syndrome (SSNS).

Purpose of the Study:

  • To review recent findings in the genetics and podocyte biology of Minimal Change Disease (MCD).
  • To discuss the proposed mechanisms, including circulating factors and immune system involvement, in MCD pathogenesis.
  • To highlight the need for novel biomarkers for predicting disease activity and treatment response in MCD.

Main Methods:

  • Review of recent literature on genetics, podocyte biology, and immunology in Minimal Change Disease (MCD).
  • Analysis of findings from whole-exome sequencing in familial SSNS cases.
  • Discussion of proposed animal models and circulating factors implicated in MCD.

Main Results:

  • Pathogenic mutations have been identified in familial SSNS, providing insights into podocyte function.
  • Circulating permeability factors and T lymphocyte dysfunction are implicated in the majority of MCD cases.
  • Rituximab's efficacy suggests B cell involvement, further complicating the understanding of MCD pathogenesis.

Conclusions:

  • Understanding the interplay between genetic factors, podocyte biology, and immune dysregulation is crucial for elucidating MCD mechanisms.
  • Further research into circulating factors and podocyte signaling pathways is needed to develop effective biomarkers.
  • Distinguishing MCD from other glomerular diseases like FSGS and predicting treatment responses remain clinical challenges.